Virtual Library

Start Your Search

David Hodge



Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-18 - The Impact of Patient Age on Clinical Outcomes in NSCLC: A National Study (ID 14182)

      16:45 - 18:00  |  Author(s): David Hodge

      • Abstract

      Background

      Treatment of NSCLC is rapidly advancing. Clinical outcomes and treatment modalities for patients in each age group remain unknown. This study investigates the treatment modalities in each age group and the impact of patients’ age on survival.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The National Cancer Database with NSCLC between 2004-2014 was used. Overall survival (OS) and treatments were analyzed by age groups, accounting for multivariates.

      4c3880bb027f159e801041b1021e88e8 Result

      A total of 2,327,158 NSCLC patients were included. Median OS is 114.6, 76.7, 52.6 and 33 months for stage I lung cancer patients at age <60, 60-69, 70-79 and ≥ 80 respectively (p<0.0001). Median OS is 7, 5.9, 4.6 and 3.3 months for stage IV patients at age <60, 60-69, 70-79 and ≥ 80 respectively (p<0.0001). The impact of age on survival is cross all stages. Younger patients are associated with larger tumor size and higher percentage of stage V at time of diagnosis. Patients with age ≥ 80 are associated with high income, high education and pacific region. Despite comparable comorbidity, patients with age ≥ 80 are treated differently and received much less aggressive therapy at each stage (p<0.0001).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The overall survival of NSCLC is significantly impacted by patient’s age. Under-treatment in elderly patients might contribute to poor survival.

      figure 1.jpg

      final tabel 1.jpg

      6f8b794f3246b0c1e1780bb4d4d5dc53

  • +

    P2.06 - Mesothelioma (Not CME Accredited Session) (ID 955)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.06-24 - The Impact of Demographic and Socioeconomic Factors on Survival of Patients with Mesothelioma in the USA (ID 14073)

      16:45 - 18:00  |  Author(s): David Hodge

      • Abstract
      • Slides

      Background

      Malignant Pleural mesothelioma (MPL) is a rare cancer with about 3000 new cases diagnosed each year in the USA. It has poor prognosis with 5 year survival rate of 10%. We performed a national study to assess the impact of demographic and socioeconomic factors on survival of patients with MPL.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Patients with MPL diagnosed between 2004-2014 were identified from the National Cancer Database (NCDB). Demographic and socioeconomic factors were collected. The impact on survival was evaluated with Cox regression model after adjusting for the variables.

      4c3880bb027f159e801041b1021e88e8 Result

      Total of 24826 patients with MPL were included. Median age at diagnosis was 73. Majority of patients were men (75 %), white (93%), insured (97%), lived in a metro area (84%) and treated at an academic facility (64%). Most patients lived in either eastern or central geographic location (45% and 39% respectively). Median overall survival (OS) was 9.8 months. Women had significantly better OS (12.4 months) vs men (9.3 months). (Table 1) OS was better with younger age (16.6 months for patients < 60; 12.4 months for 60-69; 9.9 months for 70-79 and 5.6 months for ≥ 80). Other factors associated with better OS included early stage, lower comorbidity, higher income and treatment at an academic facility. Neither insurance status nor education level had any impact on OS. Race did not impact survival except for Native Americans and Alaskans (represented only 0.2 % of patients) who had better OS compared to Whites.

      table 1.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      In this largest analysis exploring socio-demographic factors affecting MPL outcomes, we note some disparities. While some of these factors are non-modifiable, others including access to healthcare, income and treating facility type are modifiable. These must be addressed to minimize disparities in outcomes and realize maximal benefit for patients with this incurable malignancy.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.